NCT06849245 Εffectiveness of a Digital Social Intervention in Primary Care
| NCT ID | NCT06849245 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Queen Mary University of London |
| Condition | Asthma Intermittent, Uncontrolled |
| Study Type | INTERVENTIONAL |
| Enrollment | 600 participants |
| Start Date | 2025-02-25 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 600 participants in total. It began in 2025-02-25 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to deliver a definitive randomised controlled trial to measure the effectiveness and assess cost-effectiveness of a digital social intervention for patients with asthma, composed of promoting engagement with online peer support in a primary care consultation, followed by engagement with online peer support for 12 months. The main questions/objectives this study aims to answer/address are: * Does promoting engagement with an online health community in primary care help people with troublesome asthma to experience fewer asthma symptoms? * To assess cost-effectiveness of the intervention (including quality of life, well-being, use of healthcare services etc); stakeholder satisfaction (patients and healthcare professionals) with the intervention; fidelity of protocol delivery; context in which positive outcomes can be triggered.
Eligibility Criteria
Inclusion Criteria: To participate in the study, participants will need to: * Be adult asthma patients (aged 18 to 99) who have expressed their interest in digital social interventions in the recruitment survey. * Report troublesome asthma (i.e. an ACT score of less than 20) in the recruitment survey). * Be competent to consent for themselves, as determined by the healthcare professional delivering the consultation. There are no specific criteria for selecting participants for the exit interviews (a convenience sample of patients and clinicians will be used and recruitment will continue until data saturation). Exclusion Criteria: * Patients who are already members of the Asthma + Lung UK online health community or other asthma online health communities/Facebook groups (i.e. general use of social media will not prevent participation). * Palliative or end of life patients. * Patients receiving institutional long-term care (receiving total care in residential homes or living in nursing homes). * Patients considered unsuitable to take part in the study by their general practitioners/nurses. There are no specific criteria for selecting participants for the exit interviews (a convenience sample of patients and clinicians will be used and recruitment will continue until data saturation).
Contact & Investigator
Anna De Simoni, PhD
PRINCIPAL INVESTIGATOR
Clinical Reader in Primary Care Research, Queen Mary University of London
Frequently Asked Questions
Who can join the NCT06849245 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Asthma Intermittent, Uncontrolled. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06849245 currently recruiting?
Yes, NCT06849245 is actively recruiting participants. Contact the research team at a.desimoni@qmul.ac.uk for enrollment information.
Where is the NCT06849245 trial being conducted?
This trial is being conducted at Exeter, United Kingdom, Leicester, United Kingdom, London, United Kingdom, Newcastle upon Tyne, United Kingdom and 1 additional location.
Who is sponsoring the NCT06849245 clinical trial?
NCT06849245 is sponsored by Queen Mary University of London. The principal investigator is Anna De Simoni, PhD at Clinical Reader in Primary Care Research, Queen Mary University of London. The trial plans to enroll 600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.